Littérature scientifique sur le sujet « EXtremely Drug Resistant Tuberculosis »
Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres
Sommaire
Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « EXtremely Drug Resistant Tuberculosis ».
À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.
Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.
Articles de revues sur le sujet "EXtremely Drug Resistant Tuberculosis"
Polsfuss, Silke, Sabine Hofmann-Thiel, Matthias Merker, David Krieger, Stefan Niemann, Holger Rüssmann, Nicolas Schönfeld, Harald Hoffmann et Katharina Kranzer. « Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment ». Clinical Infectious Diseases 69, no 7 (2 février 2019) : 1229–31. http://dx.doi.org/10.1093/cid/ciz074.
Texte intégralMigliori, G. B., R. Centis, L. D'Ambrosio, A. Spanevello, E. Borroni, D. M. Cirillo et G. Sotgiu. « Totally Drug-Resistant and Extremely Drug-Resistant Tuberculosis : The Same Disease ? » Clinical Infectious Diseases 54, no 9 (9 avril 2012) : 1379–80. http://dx.doi.org/10.1093/cid/cis128.
Texte intégralAntonenko, Kate, Valentin Kresyun et Peter Antonenko. « Mutations leading to drug-resistant Mycobacterium tuberculosis infection in Ukraine ». Open Medicine 5, no 1 (1 février 2010) : 30–35. http://dx.doi.org/10.2478/s11536-009-0114-6.
Texte intégralAllué-Guardia, Anna, Rajagopalan Saranathan, John Chan et Jordi B. Torrelles. « Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis ». International Journal of Molecular Sciences 22, no 2 (13 janvier 2021) : 735. http://dx.doi.org/10.3390/ijms22020735.
Texte intégralMumena, David Kajoba, Geoffrey Kwenda, Caroline Wangari Ngugi et Andrew Kimanga Nyerere. « Drug-Resistant Tuberculosis Types and Their Treatment Regimens Using First-Line, Second-Line Injectable, Third-Line, Fluoroquinolones, Aminoglycosides, Cyclic Polypeptides, Novel and Repurposed Anti-Tuberculosis Drugs ». Journal of Biomedical Research & ; Environmental Sciences 3, no 8 (septembre 2022) : 988–93. http://dx.doi.org/10.37871/jbres1542.
Texte intégralShen, Xin, Guo-miao Shen, Jie Wu, Xiao-hong Gui, Xia Li, Jian Mei, Kathryn DeRiemer et Qian Gao. « Association between embB Codon 306 Mutations and Drug Resistance in Mycobacterium tuberculosis ». Antimicrobial Agents and Chemotherapy 51, no 7 (16 avril 2007) : 2618–20. http://dx.doi.org/10.1128/aac.01516-06.
Texte intégralPecho-Silva, Samuel, Ana Claudia Navarro-Solsol, Vicky Panduro-Correa, Jorge L. Maguina, Ali A. Rabaan, Luis Rene Quiroz-Ramirez, Kovy Arteaga-Livias et Alfonso J. Rodriguez-Morales. « The first successful cochlear implant in Latin America after severe aminoglycoside-induced ototoxicity in a Peruvian patient cured of extensively drug-resistant tuberculosis ». Revista del Cuerpo Médico Hospital Nacional Almanzor Aguinaga Asenjo 15, no 4 (8 février 2023) : 622–25. http://dx.doi.org/10.35434/rcmhnaaa.2022.154.1501.
Texte intégralYadav, Snehlata, et Balasubramanian Narasimhan. « New Insights in Design and Development of Antitubercular Drugs ». Current Bioactive Compounds 16, no 1 (20 février 2020) : 13–23. http://dx.doi.org/10.2174/1573407215666190409153756.
Texte intégralShaji, Jessy, et Mahmood Shaikh. « DRUG-RESISTANT TUBERCULOSIS : RECENT APPROACH IN POLYMER BASED NANOMEDICINE ». International Journal of Pharmacy and Pharmaceutical Sciences 8, no 10 (12 août 2016) : 1. http://dx.doi.org/10.22159/ijpps.2016v8i10.11295.
Texte intégralVelayati, A. A., P. Farnia, M. A. Merza, G. K. Zhavnerko, P. Tabarsi, L. P. Titov, J. Ghanavei et al. « New insight into extremely drug-resistant tuberculosis : using atomic force microscopy ». European Respiratory Journal 36, no 6 (30 novembre 2010) : 1490–93. http://dx.doi.org/10.1183/09031936.00064510.
Texte intégralThèses sur le sujet "EXtremely Drug Resistant Tuberculosis"
Smith, Louise. « Resilience of the partners of long term hospitalised patients with multidrug-resistant (MDR) and extreme drug-resistant (XDR) tuberculosis (TB) ». Thesis, Nelson Mandela Metropolitan University, 2013. http://hdl.handle.net/10948/d1020913.
Texte intégralSeddon, James Alexander. « Drug-resistant tuberculosis in children ». Thesis, London School of Hygiene and Tropical Medicine (University of London), 2012. http://researchonline.lshtm.ac.uk/4646555/.
Texte intégralPatel, Fadheela. « Development of a cost-effective drug sensitivity test for multi-drug resistant and extensively drug-resistant tuberculosis ». Thesis, Cape Peninsula University of Technology, 2010. http://hdl.handle.net/20.500.11838/1496.
Texte intégralThe World Health Organisation estimates that nine million people are infected with tuberculosis (TB) every year of which ninety-five percent live in developing countries. Africa has one of the highest incidences of TB in the world. but few of its countries are equipped to diagnose drug-resistant TB. This study aimed to develop a robust. yet simple and cost-effective assay. which would require minimal sophisticated instrumentation and specialised personnel that would make drug sensitivity screening for multi-drug resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) accessible to resource-poor high-burden settings. A four-quadrant colorimetric agar plate method was developed which showed good specificity (97.3%-100%) and sensitivity (77.8%-100%) compared to the polymerase chain reaction (PCR) method used as gold standard. Agreement between the methods. using Simple Kappa Coefficients. ranged between very good and excellent. all with high statistical significance (P < 0.0001). The currently used BACTEC MGIT SIREN sensitivity assay coupled with the E-test® strip method. as routinely used in the TB reference laboratory. was compared and showed excellent comparison with the newlydeveloped plate method. for each antibiotic tested. as well as the resultant monoresistant, MDR- or XDR-TB diagnoses. Moreover. the new method was found to be extremely cost-effective. priced at half the cost of a peR assay. These four quadrant plates. with a colorimetric indicator and selected antibiotics. can be considered as an economic altemative or a complimentary method for laboratories wishing to reduce the cost and complexity for TB drug sensitivity testing. Routine diagnostic testing would thus be made more accessible and affordable to laboratories that are not presently diagnosing drug resistant TB. therefore enhancing case detection and treatment in the resource-poor settings hardest hit by this curable disease.
Krüüner, Annika. « Drug-resistant Mycobacterium tuberculosis in Estonia / ». Stockholm, 2003. http://diss.kib.ki.se/2003/91-7349-455-0/.
Texte intégralDubiniecki, Christine. « Drug resistant tuberculosis in Montreal 1992-1995 ». Thesis, McGill University, 2001. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=33751.
Texte intégralStudy design. Retrospective descriptive analysis Study population. All culture proven TB patients reported to the Montreal Regional Health Board aged 0--49 for 1992--1994 and 0--18 years for 1995.
Results. Drug resistant TB was found in 18.3% of culture-proven TB cases. The rate of INH resistance in our study cohort was 10.6%. Two percent of TB cases were found to have MDR-TB. Only 3 TB cases (0.9%) in our study cohort developed acquired drug resistance over the study period. Previous history of TB was associated with a 3.9 times greater risk of drug resistant TB.
Conclusions. Drug resistance is a significant problem in Montreal that continues to hinder TB treatment and control. Previous history of tuberculosis is a strong predictor of drug resistance. In addition, immigration from individual countries was not associated with an increase in the rate of drug resistance. Nonetheless, country-specific drug resistance rates may serve to predict the likelihood of drug resistant TB among the foreign-born in Canada.
Ford, Christopher Burton. « The Evolution of Drug Resistant Mycobacterium Tuberculosis ». Thesis, Harvard University, 2012. http://dissertations.umi.com/gsas.harvard:10596.
Texte intégralShean, Karen Penelope. « Extensively drug resistant tuberculosis in South Africa ». Master's thesis, University of Cape Town, 2011. http://hdl.handle.net/11427/11620.
Texte intégralIncludes bibliographical references (leaves 161-168).
There are few data for treatment-related outcomes in patients with XDR tuberculosis in settings with high HIV prevalence. We reviewed the case records of 227 consecutively diagnosed South African patients with XDR-TB between 2002 and 2008, and analysed the records of another 115 patients, retrospectively, for adverse drug reactions (ADRs). It was found that a significant proportion of XDR-TB patients are HIV unrelated, and prognosis, regardless of HIV status, poor. Nevertheless, survival in HIV infected patients is better than previously reported, and treatment with HAART improves outcomes. The frequency of ADR’s with XDR-TB treatment regimens is high, often severe, and negatively impacts on culture conversion outcomes. These data have implications for the formulation of recommendations for control programmes in resource-poor settings.
Al-Shammaa, Zaid. « Targeting Drug-Resistant Tuberculosis Using SMART Nanotechnology Approach ». University of Cincinnati / OhioLINK, 2015. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1439310613.
Texte intégralStoffels, Karolien. « Contribution to the research on drug resistant Mycobacterium tuberculosis ». Doctoral thesis, Universite Libre de Bruxelles, 2014. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/209194.
Texte intégralFirst of all, a profound analysis of the MDR-TB situation in Belgium was conducted. It is the first retrospective population-based survey of MDR-TB in Belgium, covering a 15-year period (1994-2008). It comprises 174 patients representing more than 80% of the culture positive MDR-TB patients reported to the Belgian register, thus this study is considered of national relevance. It includes bacteriological and molecular data on the isolates as well as clinical aspects of the patients and treatment results. Considering only the patient’s first MDR-TB isolate, an increase over time was observed in the number of isolates resistant to a second-line drug as well as the total number of drugs each isolate was resistant to. XDR-TB was detected since 2002 and panresistant TB (resistant to every available antituberculosis drug) since 2009. Overall, a successful treatment outcome was obtained for 67.8% of the MDR-TB cases. Drug susceptibility testing (DST) of Mycobacterium tuberculosis to first line drugs (isoniazid, rifampicin, ethambutol and pyrazinamide) in liquid culture medium has a turn around time of at least two weeks, after identification of the positive culture (obtained after 2 to 4 weeks) from the patient’s clinical isolate. In order to provide the clinician with valuable information about the isolated mycobacteria leading to patient adapted therapy before bacteriological DST results are available, resistance is predicted by detection of mutations in certain genes of the mycobacteria. It is common practice for rifampicin (rpoB gene) and isoniazid (katG gene and/or inhA promoter region). In this MDR-TB collection, rifampicin resistant related mutations were found in 97.1% (168/173) of the clinical isolates and isoniazid resistant related mutations in 94.1% (160/170). The pncA, embB and gyrA genes have been sequenced to identify possible mutations because of their possible involvement with resistance to pyrazinamide, ethambutol and the fluoroquinolones respectively. However, little is known about the resistance prediction value of the mutations in these genes.
The study is also the first study on the molecular epidemiology of MDR-TB in the country. DNA fingerprinting showed a large diversity of strains (67% of the patients were infected by a strain with a unique pattern) and further epidemiological examination revealed limited local transmission of MDR-TB in Belgium.
The second part investigated the pncA gene and its association with pyrazinamide resistance in MDR-TB isolates from Belgium and in vitro cultured spontaneous mutants. The genetic analysis showed that 98.3% (59/60) of the Belgian clinical MDR pyrazinamide resistant (PZAR) isolates present a mutation in the pncA gene. We found 1.7% (1/60) of the PZAR MDR-isolates encoding wild type pncA and flank. A total (PZAR and PZAS) of 41 different amino acid changes, 3 protein truncations and 5 frameshifts were observed including eight novel mutations: 8Asp>Ala, 13Phe>Leu, 64Tyr>Ser, 107Glu>stop, 143Ala>Pro, 172Leu>Arg and frameshifts starting in codon 55 and 82. Analysis of all observed mutations (i.e. in clinical isolates as well as spontaneous mutants) revealed that they are not always associated with drug resistance and that they are not scattered randomly throughout the gene, but occur rather at preferential sites such as in codons with amino acids associated with either iron or substrate binding and catalytic active sites. The frequency of in vitro mutagenesis to pyrazinamide at pH 6.0 was determined and found to be relatively high at 10-5 CFU/ml.
Finally, the in vitro activity of tobramycin and clarithromycin (with unclear efficacy against M. tuberculosis) was evaluated on 25 M. tuberculosis clinical isolates with various resistance profiles. The effect of the drugs administered together was examined for possible synergistic effect. The median minimum inhibitory concentration (MIC) of 8 µg/ml obtained for both drugs in this study is rather high but are beyond the concentrations obtained in lung tissues. This suggests that both drugs should be investigated further as potential adjuncts to the treatment of resistant TB when other alternatives have failed; in particularly through new drug delivery systems such as the Dry Power Inhaler which allows local drug deposition with high drug concentrations in the lungs but low toxicity due to limited systemic absorption. In addition, for 36% of the tested isolates a decrease of the MIC of clarithromycin by a single or twofold dilution was observed in the presence of a subinhibitory concentration of tobramycin and no antagonistic effect was seen for the remaining isolates.
This research illustrates different (laboratory) aspects in the fight against drug resistant TB, all using the Belgian TB collection: characterisation of the Belgian MDR-TB situation on bacteriological, molecular and epidemiological level; profound analysis of genomic mutations and their possible association with drug resistance; and investigation of synergistic activity of drugs with low efficacy against M. tuberculosis.
Doctorat en Sciences biomédicales et pharmaceutiques
info:eu-repo/semantics/nonPublished
Kwong, Tsz-ching, et 鄺芷晴. « The role of molecular diagnosis of drug resistant tuberculosis ». Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2015. http://hdl.handle.net/10722/208588.
Texte intégralpublished_or_final_version
Microbiology
Master
Master of Philosophy
Livres sur le sujet "EXtremely Drug Resistant Tuberculosis"
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Tuberculosis Elimination. TB elimination : Treatment of drug-resistant tuberculosis. Atlanta, Ga.] : National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination, 2012.
Trouver le texte intégralHarvard Medical School. Program in Infectious Disease and Social Change. et Open Society Institute, dir. The global impact of drug-resistant tuberculosis. Boston, MA : Program in Infectious Disease and Social Change, Dept. of Social Medicine, Harvard Medical School, 1999.
Trouver le texte intégralNguy, Shui. Drug-resistant tuberculosis : Causes, diagnosis, and treatments. Sous la direction de K'ung Zhou. Hauppauge NY : Nova Science Publishers, 2009.
Trouver le texte intégralCrofton, John. Guidelines for the management of drug-resistant tuberculosis. Geneva : World Health Organization, 1997.
Trouver le texte intégralCrofton, John Wenman. Guidelines for the management of drug-resistant tuberculosis. Geneva : World Health Organization, 1997.
Trouver le texte intégralJohn, Crofton. Guidelines for the management of drug-resistant tuberculosis. Geneva : WHO, 1997.
Trouver le texte intégralJohn, Crofton. Guidelines for the management of drug-resistant tuberculosis. Geneva : World Health Organization, 1997.
Trouver le texte intégralGuidelines on the management of drug-resistant tuberculosis. [Geneva] : World Health Organization, 1997.
Trouver le texte intégralN, Rom William, et Garay Stuart M, dir. Tuberculosis. Boston : Little, Brown, 1996.
Trouver le texte intégralMichael, Rich, et World Health Organization, dir. Guidelines for the programmatic management of drug-resistant tuberculosis. Geneva : World Health Organization, 2006.
Trouver le texte intégralChapitres de livres sur le sujet "EXtremely Drug Resistant Tuberculosis"
Dheda, Keertan, Aliasgar Esmail, Anzaan Dippenaar, Robin Warren, Jennifer Furin et Christoph Lange. « Drug-Resistant Tuberculosis ». Dans Clinical Tuberculosis, 301–26. Sixth edition. | Boca Raton, FL : CRC Press/Taylor & Francis Group, 2020. : CRC Press, 2020. http://dx.doi.org/10.1201/9781351249980-16.
Texte intégralDavies, Peter D. O. « Multi-Drug-Resistant Tuberculosis ». Dans Tuberculosis, 809–37. Berlin, Heidelberg : Springer Berlin Heidelberg, 2004. http://dx.doi.org/10.1007/978-3-642-18937-1_46.
Texte intégralLiang, Lili, Yun Ma, Xin liu et Yamin Lv. « Drug-Resistant Tuberculosis ». Dans Drug Resistance in Bacteria, Fungi, Malaria, and Cancer, 193–208. Cham : Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-48683-3_8.
Texte intégralAhmad Khan, Faiz, Greg Fox et Dick Menzies. « Drug-Resistant Tuberculosis ». Dans Handbook of Antimicrobial Resistance, 1–20. New York, NY : Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-0667-3_13-1.
Texte intégralAhmad Khan, Faiz, Greg Fox et Dick Menzies. « Drug-Resistant Tuberculosis ». Dans Handbook of Antimicrobial Resistance, 263–86. New York, NY : Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-0694-9_13.
Texte intégralBachappanavar, Nikhil, et Sinosh Skariyachan. « Combinatorial Designing of Novel Lead Molecules Towards the Putative Drug Targets of Extreme Drug-Resistant Mycobacterium tuberculosis : A Future Insight for Molecular Medicine ». Dans Essentials of Bioinformatics, Volume II, 233–81. Cham : Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-18375-2_12.
Texte intégralJohnson, Livette S., et Kent A. Sepkowitz. « Treatment of multi-drug-resistant tuberculosis ». Dans Tuberculosis, 317–30. Boston, MA : Springer US, 1995. http://dx.doi.org/10.1007/978-1-4899-2869-6_13.
Texte intégralXiao, Heping, Shenjie Tang, Wei Sha, Qing Zhang et Jin Zhao. « Drug-Resistant TB ». Dans Handbook of Global Tuberculosis Control, 135–56. Boston, MA : Springer US, 2017. http://dx.doi.org/10.1007/978-1-4939-6667-7_10.
Texte intégralSchluger, Neil W. « Extensively Drug-Resistant Tuberculosis ». Dans Emerging Infections 8, 337–53. Washington, DC, USA : ASM Press, 2014. http://dx.doi.org/10.1128/9781555815592.ch17.
Texte intégralAuld, Sara C., Neel R. Gandhi et James C. M. Brust. « Drug-Resistant Tuberculosis and HIV ». Dans HIV and Tuberculosis, 203–37. Cham : Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-29108-2_10.
Texte intégralActes de conférences sur le sujet "EXtremely Drug Resistant Tuberculosis"
ankale, Padmaraj, Girija Nair, Abhay Uppe, Aleena Mathew et Ria shah. « Socioeconomic Conditions Contributing to Multi Drug Resistant (MDR) and Extremely Drug Resistant(XDR) Tuberculosis ». Dans ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa2727.
Texte intégralSung, Nacmoon, Jeong Su Cho, Ki-Hong Kim, Jong-Ki Kim, JinHee Jung, Hyungseok Kang, Seungkyu Park et Sanghoon Jheon. « Inactivation Of Multidrug Resistant (MDR)- And Extremely Drug Resistant (XDR)-Mycobacterium Tuberculosis Strains By Using Photodynamic Therapy (PDT) ». Dans American Thoracic Society 2010 International Conference, May 14-19, 2010 • New Orleans. American Thoracic Society, 2010. http://dx.doi.org/10.1164/ajrccm-conference.2010.181.1_meetingabstracts.a3170.
Texte intégralWaghmare, Manoj, Ketaki Utpat, Unnati Desai et Jyotsna Joshi. « Drug resistant tuberculosis at a drug resistant tuberculosis centre, India- Analysis of outcome ». Dans ERS International Congress 2017 abstracts. European Respiratory Society, 2017. http://dx.doi.org/10.1183/1393003.congress-2017.pa2729.
Texte intégralArtiom, Jucov, et Lesnic Evelina. « Social determinants of drug-susceptible and drug resistant tuberculosis ». Dans ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2749.
Texte intégralCarroll, Matthew W., M. S. Lee, T. S. Song, Ying Cai, J. S. Lee, Y. M. Lee, L. E. Via et al. « Linezolid For Extensively Drug Resistant Pulmonary Tuberculosis ». Dans American Thoracic Society 2011 International Conference, May 13-18, 2011 • Denver Colorado. American Thoracic Society, 2011. http://dx.doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a1838.
Texte intégralHidayathillah, Ariska Putri, Chatarina Umbul W et Hari Basuki N. « Index Predictive of Drug Resistant Tuberculosis (MDR-TB) on Tuberculosis Patients ». Dans The 2nd International Symposium of Public Health. SCITEPRESS - Science and Technology Publications, 2017. http://dx.doi.org/10.5220/0007511902270231.
Texte intégralCampos, Michael Ramírez, Diana C. Rodríguez et Alvaro D. Orjuela-Cañón. « Molecular Compounds Proposal for Drug-Resistant Tuberculosis in the Drug Discovery Process ». Dans 2023 IEEE Colombian Conference on Applications of Computational Intelligence (ColCACI). IEEE, 2023. http://dx.doi.org/10.1109/colcaci59285.2023.10225875.
Texte intégralChopra, Manu, C. D. S. Katoch, G. D. S. Madan et Barun Chakrabarty. « Outcomes of directly observed treatment for drug resistant tuberculosis ». Dans ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa2687.
Texte intégralMoodliar, R., V. Aksenova, M. V. G. Frias IV, J. van de Logt, S. Rossenu, E. Birmingham, C. Kambili et al. « Bedaquiline for Multi Drug-Resistant, Including Extensively or Pre-Extensively Drug-Resistant, Pulmonary Mycobacterium Tuberculosis in Children ». Dans American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a1050.
Texte intégralMadhav, Bhumika, Aparna Iyer et T. K. Jayalakshmi. « Side effect profile of 2ndline drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis ». Dans Annual Congress 2015. European Respiratory Society, 2015. http://dx.doi.org/10.1183/13993003.congress-2015.pa2708.
Texte intégralRapports d'organisations sur le sujet "EXtremely Drug Resistant Tuberculosis"
Yusim, Karina, Bette T. M. Korber, Shihai Feng et Chang-Shung Tung. Compensatory mutation in RpoC restores fitness to rifampicin-resistant multi-drug resistant Mycobacterium tuberculosis. Office of Scientific and Technical Information (OSTI), août 2012. http://dx.doi.org/10.2172/1049993.
Texte intégralLau, J., et B. Baker. Isothermal DNA Assay to Detect Drug-Resistant Tuberculosis for Point-of-Care Diagnostics. Office of Scientific and Technical Information (OSTI), août 2013. http://dx.doi.org/10.2172/1093910.
Texte intégralRapid tests for diagnosing drug resistant tuberculosis are accurate and may be cost effective. National Institute for Health Research, novembre 2015. http://dx.doi.org/10.3310/signal-000145.
Texte intégral